Key Developments For Cepheid
Cepheid (CPHD.O) (Nasdaq)
Cepheid, Inc. Narrows FY 2009 Outlook; Revenue Outlook To A Range In Line With Analysts' Estimates
Cepheid, Inc. announced that for fiscal 2009, it expects total revenue to be in the range of $165-$169 million, net loss per share in the range of $0.42-$0.45 and non-GAAP net loss per share in the range of $0.13-$0.16. According to Reuters Estimates, analysts were expecting the Company to report revenues of $166 million for the same period.
Cepheid, Inc. Issues Q3 2009 Revenue Outlook In Line With Analysts' Estimates
Cepheid, Inc. announced that it currently expects total revenue for the third quarter 2009 to be approximately $41 million. According to Reuters Estimates, analysts on an average are expecting the Company to report revenue of $41 million for the same period.
Cepheid, Inc. Announced FDA Clearance For Xpert HemosIL FII & FV Test
Cepheid, Inc. announced that it has received clearance from the U.S. Food & Drug Administration (FDA) to market its Xpert HemosIL FII & FV test. The test detects Factor II (FII) and Factor V Leiden (FV) genetic variations associated with thrombophilia, an increased risk of blood clots (thrombosis). Xpert HemosIL FII & FV delivers results in just over thirty minutes using a single GeneXpert cartridge. Developed and manufactured by the Company, the test will be available worldwide through a partnership with IL, the exclusive worldwide distributor for the Xpert HemosIL FII & FV test.
Cepheid, Inc. Announces Development Of Flu A Panel Test
Cepheid, Inc. announced the accelerated development of a Flu A (Influenza Virus) Panel test for use on the GeneXpert System. The test will be designed to provide 45-minute identification of Flu A infection, with specific presumptive identification of seasonal H1, seasonal H3, and H1N1 novel strain types. Following review of the Request for Consideration for Emergency Use Authorization (EUA) by the U.S. Food & Drug Administration (FDA), the test is expected to be authorized for use during the upcoming influenza season, with product shipments beginning in January 2010. Subsequent to the EUA request for consideration by the FDA, the test will be made available in Europe as a CE IVD product.
Cepheid, Inc. Reiterates FY 2009 Revenue Outlook; Lowers FY 2009 EPS Outlook
Cepheid, Inc. announced that for fiscal 2009, it continues to expect revenue to be in the range of $164 million to $170 million. The Company has reduced the loss per share guidance ranges from previously announced guidance by $0.01 to reflect the patent license amortization adjustment. The Company expects net loss in the range of $(0.43) to $(0.48) per share; non-GAAP net loss in the range of $(0.12) to $(0.18) per share. According to Reuters Estimates, analysts on an average were expecting the Company to report revenue of $166 million and earnings per share (EPS) of $(0.44) for fiscal 2009.
